Roche’s Ocrevus treatment showed fewer patients with relapsing multiple sclerosis needed walking aids, the company said on Oct. 13
Lomecel-B – Longeveron’s proprietary off-the-shelf cell therapy for aging frailty – failed the six-minute walk test (6MWT) endpoint of a Phase IIb study, according to a statement published by the Miami-based biotech on Aug. 13.
Stealth BioTherapeutics Corp.’s shares crashed after the company’s lead neuromuscular disorder product candidate failed to help patients walk better and reduce fatigue.
Apple Inc. launched an app that will let users of the company’s devices to enroll in three health studies, allowing them to share health-related data for medical research.
The world economy could be boosted by as much as $100 billion a year if employers successfully encouraged their staff to meet World Health Organization guidelines on exercise, according to an analysis of the economic impact of activity.
The U.S. Supreme Court declined to hear Acorda Therapeutics Inc.’s appeal of a lower court ruling that allowed generic versions of the company’s multiple sclerosis treatment Ampyra.